9.11
-0.25(-2.67%)
Currency In USD
Previous Close | 9.36 |
Open | 9.01 |
Day High | 9.34 |
Day Low | 8.84 |
52-Week High | 20.6 |
52-Week Low | 7 |
Volume | 115,140 |
Average Volume | 87,142 |
Market Cap | 188.66M |
PE | -2.28 |
EPS | -4 |
Moving Average 50 Days | 9.85 |
Moving Average 200 Days | 11.36 |
Change | -0.25 |
If you invested $1000 in Amarin Corporation plc (AMRN) 10 years ago, it would be worth $198.91 as of April 20, 2025 at a share price of $9.11. Whereas If you bought $1000 worth of Amarin Corporation plc (AMRN) shares 5 years ago, it would be worth $67.78 as of April 20, 2025 at a share price of $9.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
GlobeNewswire Inc.
Apr 09, 2025 11:30 AM GMT
Action Taken to Maintain Company’s Nasdaq ListingDUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today confirmed that April 11, 2025 will be the effective date for the Company’s previously ann
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
GlobeNewswire Inc.
Apr 07, 2025 11:30 AM GMT
DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member o
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
GlobeNewswire Inc.
Mar 31, 2025 12:00 PM GMT
– Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action and Utility as A Complementary Therapy for Residual Risk Reduction in Combination with Statins in Important Patient Sub-Categories –DUBLIN and BRIDGEWATER, N.J.,
Data not available